Several studies support the concept that tumour-associated macrophages protect cancer cells from the antitumour immune responses.19,20 Because we have previously found that a monocyte subset co-expressing PD-L1 and FKBP51s appeared to be associated with resistance to ipilimumab, we measured the counts of FKBP51s+PD-L1+ CD14 mononuclear cells in our study population, at baseline and during the treatments. This evidence concerns the gene CD14 and neoplasm.